Université Côte d'Azur, INSERM, C3M, Nice, France.
Cancer Research UK Beatson Institute, Institute of Cancer Sciences, University of Glasgow, Switchback Road, Glasgow, UK.
Cell Rep. 2017 Sep 19;20(12):2846-2859. doi: 10.1016/j.celrep.2017.08.087.
Mitophagy is an evolutionarily conserved process that selectively targets impaired mitochondria for degradation. Defects in mitophagy are often associated with diverse pathologies, including cancer. Because the main known regulators of mitophagy are frequently inactivated in cancer cells, the mechanisms that regulate mitophagy in cancer cells are not fully understood. Here, we identified an E3 ubiquitin ligase (ARIH1/HHARI) that triggers mitophagy in cancer cells in a PINK1-dependent manner. We found that ARIH1/HHARI polyubiquitinates damaged mitochondria, leading to their removal via autophagy. Importantly, ARIH1 is widely expressed in cancer cells, notably in breast and lung adenocarcinomas; ARIH1 expression protects against chemotherapy-induced death. These data challenge the view that the main regulators of mitophagy are tumor suppressors, arguing instead that ARIH1-mediated mitophagy promotes therapeutic resistance.
自噬是一种进化上保守的过程,它选择性地靶向受损的线粒体进行降解。自噬缺陷常与多种病理有关,包括癌症。由于自噬的主要已知调节因子在癌细胞中经常失活,因此癌细胞中调节自噬的机制尚未完全清楚。在这里,我们发现了一种 E3 泛素连接酶(ARIH1/HHARI),它以 PINK1 依赖性的方式在癌细胞中引发自噬。我们发现 ARIH1/HHARI 多泛素化损伤的线粒体,导致它们通过自噬被清除。重要的是,ARIH1 在癌细胞中广泛表达,特别是在乳腺癌和肺腺癌中;ARIH1 的表达可防止化疗引起的死亡。这些数据挑战了自噬的主要调节因子是肿瘤抑制因子的观点,而是认为 ARIH1 介导的自噬促进了治疗耐药性。